As the largest lever to lower health care costs for self-insured employers, World Class Health will use the new funding to continue expanding the industry's most expansive U.S. and global Centers of Excellence network.
Read MoreThe platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025.
Read More
May 1, 2025 - Article has been updated to reflect changes to remove George Church from the bulleted list and update his title following his quote.
Groundbreaking longevity research initiative brings together leading scientists and institutions to decode the genetic basis of extreme lifespan
Read MoreRobotic smelltech by AI Nose moves from concept to integration in weeks
Partnership fast-tracks robotic smell integration as global service robotics market nears $40.6B, Japan $1.2B
Read More
Virtue Recovery Center Offers Veterans a Place to Heal and Be Heard
Virtue Recovery Center in Las Vegas offers veterans compassionate, personalized care for PTSD, addiction, and mental health recovery.
Read MoreRecord order for Wattbike builds on brand momentum and the launch of the Air Pro, the next generation of the best-selling elite performance training bike used globally by professional sports teams
Geographic expansion, especially in the US, is key to the strategy of TRNR acquiring the UK-based Wattbike
Wattbikes are installed in more than 3,000 Gyms in the UK but only a few hundred in the US - providing a significant opportunity for US growth
Read More
With the global CBD market expected to exceed $60 billion by 2030, and the mental wellness industry surging past $500 billion, CBD Life Sciences Inc. (OTC: CBDL) is strategically positioning itself at the center of two of the fastest-growing markets in modern health.
Read More
"For too long, these DEA officials, Thomas Prevoznik, Matthew Strait and Aarathi Haig have operated with impunity while denying patients access to critical medicines," said Duane Boise, CEO of MMJ BioPharma Cultivation.
Read More
MMJ's DEA lawsuit continues moving through the federal courts. The 8 organizations who have been issued DEA federal cannabis registrations since 2021, all are incapable of growing pharmaceutical-grade marijuana and 7 are now either inactive or bankrupt.
Read MoreCrofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's PRIME program for novel medicines targeting unmet medical needs and the FDA's Breakthrough Therapies program
Read MoreThe statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium
Late-breaker abstract accepted by MASCC shows additional significant results for breast cancer subgroup
Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer
A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting
Read More
